Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for tough-to-treat throat cancer

NCT ID NCT06509009

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 31 times

Summary

This study tests a mix of three drugs (nimotuzumab, toripalimab, and chemotherapy) as a first treatment for people whose nasopharyngeal cancer has come back or spread. About 30 adults with EGFR-positive tumors will receive the combination to see if it shrinks tumors and delays progression. The goal is to control the disease, not cure it, and researchers will monitor side effects closely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA BY AJCC V8 STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medcial Science and Peking Union Medical College

    RECRUITING

    Beijing, Beijing Municipality, 1000000, China

Conditions

Explore the condition pages connected to this study.

NASOPHARYNGEAL CARCINOMA BY AJCC V8 STAGE